Real-world outcomes associated with bevacizumab combined with chemotherapy in platinum-resistant ovarian Cancer
CONCLUSION: Real-world outcomes with bevacizumab in PL-R OC are inferior to those in the pivotal clinical trial. Survival has not significantly improved since funding became publicly available, indicating a substantial efficacy-effectiveness gap between trial and real-world outcomes. Median OS and ToT were significantly better when bevacizumab was given with paclitaxel.PMID:38281412 | DOI:10.1016/j.ygyno.2024.01.027
Source: Gynecologic Oncology - Category: Cancer & Oncology Authors: Gordon Taylor Moffat Weidong Kong Helen J MacKay Jacob McGee Christopher M Booth Josee-Lyne Ethier Source Type: research
More News: Avastin | Canada Health | Cancer | Cancer & Oncology | Chemotherapy | Clinical Trials | Databases & Libraries | Ovarian Cancer | Ovaries